Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex.

IF 4.2 2区医学 Q1 INFECTIOUS DISEASES

Expert Review of Anti-infective Therapy Pub Date : 2024-09-08 DOI:10.1080/14787210.2024.2400703

Jordan R Covvey, Anthony J Guarascio

{"title":"Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex.","authors":"Jordan R Covvey, Anthony J Guarascio","doi":"10.1080/14787210.2024.2400703","DOIUrl":null,"url":null,"abstract":"Introduction: Infections with Acinetobacter baumannii-calcoaceticus complex (ABC) pose difficulty for clinicians given a limited arsenal of effective antimicrobials. Sulbactam/durlobactam provides a novel treatment option for patients experiencing hospital- or ventilator-acquired pneumonia with susceptible strains.Areas covered: This review provides a comprehensive discussion of sulbactam/durlobactam, including basic characteristics, in vitro activity, and clinical trial data supporting its use for the treatment of ABC. Manufacturer's data, published literature to date, and conference data are utilized in this review.Expert opinion: Sulbactam/durlobactam offers clinicians a new and effective treatment option for resistant ABC infection. Sulbactam, when combined with durlobactam, displays enhanced potency against ABC isolates, which has translated into positive clinical outcomes observed in clinical trials and post-marketing case studies. Although overall treatment indications and clinical experience are limited to date, sulbactam/durlobactam offers a familiar and favorable safety profile in comparison with alternative agents. Factors associated with use of combination antibiotic therapy, availability of commercial drug susceptibility testing, and cost-effectiveness are all currently key considerations for sulbactam/durlobactam use.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anti-infective Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14787210.2024.2400703","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Infections with Acinetobacter baumannii-calcoaceticus complex (ABC) pose difficulty for clinicians given a limited arsenal of effective antimicrobials. Sulbactam/durlobactam provides a novel treatment option for patients experiencing hospital- or ventilator-acquired pneumonia with susceptible strains.

Areas covered: This review provides a comprehensive discussion of sulbactam/durlobactam, including basic characteristics, in vitro activity, and clinical trial data supporting its use for the treatment of ABC. Manufacturer's data, published literature to date, and conference data are utilized in this review.

Expert opinion: Sulbactam/durlobactam offers clinicians a new and effective treatment option for resistant ABC infection. Sulbactam, when combined with durlobactam, displays enhanced potency against ABC isolates, which has translated into positive clinical outcomes observed in clinical trials and post-marketing case studies. Although overall treatment indications and clinical experience are limited to date, sulbactam/durlobactam offers a familiar and favorable safety profile in comparison with alternative agents. Factors associated with use of combination antibiotic therapy, availability of commercial drug susceptibility testing, and cost-effectiveness are all currently key considerations for sulbactam/durlobactam use.

查看原文本刊更多论文

舒巴坦-杜鲁巴坦用于治疗鲍曼不动杆菌-醋酸钙复合菌。

导言：由于有效抗菌药物有限，鲍曼不动杆菌-铜绿假单胞菌复合菌（ABC）感染给临床医生带来了困难。舒巴坦/杜洛巴坦为感染易感菌株的医院或呼吸机获得性肺炎患者提供了一种新的治疗选择：本综述全面讨论了舒巴坦/杜洛巴坦，包括其基本特性、体外活性以及支持其用于治疗 ABC 的临床试验数据。本综述采用了生产商数据、迄今为止已发表的文献以及会议数据：舒巴坦/杜洛巴坦为临床医生提供了一种治疗耐药 ABC 感染的有效新方法。舒巴坦与杜鲁巴坦联用后，对ABC分离菌株的效力增强，这已转化为临床试验和上市后病例研究中观察到的积极临床结果。虽然迄今为止总体治疗适应症和临床经验有限，但舒巴坦/杜鲁巴坦与其他药物相比，具有熟悉和良好的安全性。与使用联合抗生素疗法相关的因素、商业药敏试验的可用性以及成本效益都是目前使用舒巴坦/杜鲁巴坦的主要考虑因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anti-infective Therapy 医学-药学

CiteScore

11.20

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.